(269 days)
The Quantisal II Oral Fluid Collection Device is intended for the collection, preservation and transport of oral fluid specimens for tetrahydrocannabinol (THC), benzoylecgonine, cocaine, oxycodone, hydrocodone, bacetylmorphine, phencyclidine, amphetamine, buprenorphine, methadone, benzodiazepines and tramadol. This device is for prescription use only.
The Quantisal II Oral Fluid Collection Device is intended for the collection, preservation and transport of oral fluid. An oral fluid specimen is collected by placing two cellulose pads affixed to a polypropylene stem (Collector) under the tongue of an individual until a defined volume of saliva has saturated the cellulose pads. The defined volume taken up by the cellulose pads is indicated by coloration (blue) in a window on the stem (volume adequacy). The collector is then separated into two specific pads/stems and transferred into two separate polypropylene tubes (provided) both containing a specific volume of preservative buffer. The tubes are stoppered with provided caps. The specimens are then ready for storage or transport. The design of two specific pads/stems allows for one aliquot to be used for screening and confirmation testing and the other aliquot to be stored as retain sample for potential second chance testing. The Quantisal II Oral Fluid Collection System collects 1 mL of neat oral fluid and dilutes it with 3 mL of preservative buffer. This results in a 1 to 4 dilution factor. Immunalysis Quantisal II Oral Fluid Collection Device is sold as a stand-alone collection device.
This document describes product testing for the Immunalysis Quantisal II Oral Fluid Collection Device, a medical device for collecting and preserving oral fluid samples for drug testing. This is not an AI/ML device, and therefore the details usually associated with an AI/ML device's acceptance criteria and study (such as MRMC studies, human reader improvement with AI assistance, or sample sizes for training sets) are not applicable.
However, based on the provided text, we can extract details regarding the device's performance characteristics and how its acceptance was established.
1. A table of acceptance criteria and the reported device performance
| Performance Characteristic | Acceptance Criteria (Implicit) | Reported Device Performance |
|---|---|---|
| Sample Volume | Consistency within 15% between collectors A and B | Confirmed consistency of 1 mL collected by each Quantisal II collector, and volume difference between A and B did not exceed 15% (for 50 volunteers and 75 known drug users). |
| Sample Collection Time | Collection time within 10 minutes | Within the claimed time of 10 minutes in over 99% of 125 subjects (50 volunteers and 75 known drug users). |
| Drug Recovery (In Vitro) | >80% of original concentration | Demonstrated >80% recovery of tested drugs. |
| Oral Fluid Sample Extraction Efficiency | Drug recovery >80% at 4 hours, >90% at 24 hours | Drug recovery was >80% at 4 hours post-collection for all drugs and reached >90% at 24 hours for all drugs, indicating complete extraction. |
| Oral Fluid Sample Stability (Ambient) | Stable x days (specific to drug) | 10 days for most drugs, 5 days for Cocaine at 8-25°C. Ongoing for refrigerated. |
| Oral Fluid Sample Stability (Refrigerated) | Stable x days (specific to drug); "B" specimen within 100+/- 10% recovery for 1 month at 2°C - 8°C | 10 days for most drugs at 2-8°C. "B" specimen retained within 100+/- 10% recovery after 1 month storage at 2°C - 8°C. |
| Sample Transportation Stability | Drug concentration within 20% of reference value | Drug concentration within 20% of reference value during 4-day (96 hours) simulated transportation at -20°C to 40°C. |
| Borosilicate Glass Vial Stability | Drug loss within ±10% of initial value after 48 hours at 25°C | Drug loss within ±10% of initial value after 48 hours storage at 25°C. |
| Clinical Specimens (Quantisal II A/B agreement) | Quantisal II A and B samples within ±15% of each other | 100% (e.g., 40/40) for all drug classes/sample types tested. |
| Clinical Specimens (Agreement with Expectorated Samples) | Quantisal II A/B agreement with expectorated samples; no false positives/negatives based on presence/absence of drugs | 100% (e.g., 40/40) for all drug classes/sample types tested. "In no case was the expectorated neat oral fluid positive and the Quantisal II collected samples negative or vice versa." |
| Expectorated Oral Fluid Samples Processed Through Quantisal II (Dipping Study) | Quantisal II A and B concentrations within 15% of each other; Quantisal II concentration within ±20% of expectoration result | 899/900 paired results met the criterion for A and B concentrations within 15% of each other. 899/900 paired results met the criterion for Quantisal II concentration within ±20% of expectoration result. |
2. Sample sizes used for the test set and the data provenance
- Sample Volume: 50 oral fluid samples from volunteers (country not specified, likely US since FDA submission), 75 oral fluid samples from known drug users (country not specified, likely US since FDA submission). Retrospective.
- Sample Collection Time: 50 oral fluid samples from volunteers, 75 oral fluid samples from known drug users. Retrospective.
- Drug Recovery (In Vitro): Oral fluid spiked with drugs at specific concentrations. Number of samples not explicitly stated but implied to be sufficient for LC-MS/MS or GC-MS testing. This is an in-vitro study.
- Oral Fluid Sample Extraction Efficiency and Stability: Oral fluid spiked with drugs. Number of samples not explicitly stated. This is an in-vitro study.
- Sample Transportation Stability: Oral fluid spiked with drugs. Number of replicates not explicitly stated for each condition, but tested in "replicates of two" within the variable temperature range. This is an in-vitro study with simulated transport conditions.
- Borosilicate Glass Vial Stability: Oral fluid spiked with drugs, initial concentration analyzed, then tested with three vials sequentially. This is an in-vitro study.
- Clinical Specimens:
- Drug-Free: 40 deidentified, unaltered clinical oral fluid samples collected by expectoration and Quantisal II for each drug class/analyte. (Total 40 drug-free per drug x 15 drugs = 600 samples for the device, and 600 for expectoration).
- Containing Drug: 40 deidentified, unaltered clinical oral fluid samples (except for Hydrocodone with 18 samples) obtained from clinical research facility, collected by expectoration and Quantisal II for each drug class/analyte. (Total ~578 samples for the device, and ~578 for expectoration).
- Provenance: Clinical research facility, "deidentified, unaltered" samples. Country of origin not explicitly stated but implied to be within the US given FDA submission. Retrospective (samples "obtained").
- Expectorated Oral Fluid Samples Processed Through Quantisal II (Dipping Study): At least 60 deidentified, unaltered drug-containing oral fluid samples collected by expectoration from a clinical research facility. A minimum of 10 samples for each drug were within ±50% of the confirmation cutoffs. Total of 900 paired results were analyzed (Implied: 60 samples x 15 drugs = 900 measurements, or 60 samples for an undisclosed mix of drugs). Retrospective (samples "collected").
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
This is not applicable as this is a device for collecting samples for chemical analysis, not an AI/ML diagnostic interpretation. The "ground truth" for the drug concentrations was established through quantitative laboratory methods (LC-MS/MS or GC-MS), which are considered objective analytical techniques rather than expert consensus.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not applicable. Ground truth was established by laboratory instrumentation (LC-MS/MS or GC-MS), not human adjudication.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This is not an AI/ML diagnostic device that involves human readers or interpretation of medical images.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Not applicable. This is a collection device, not an algorithm. The reported performance is the device's ability to collect, preserve, and transport samples for subsequent laboratory analysis.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
The ground truth for the presence and concentration of drugs in oral fluid samples was established using quantitative analytical methods: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and Gas Chromatography-Mass Spectrometry (GC-MS). These are highly sensitive and specific laboratory techniques considered gold standards for drug detection and quantification in biological matrices. For the clinical specimens, the "clinical truth" was defined by the expectorated neat oral fluid sample analyzed by LC-MS/MS or GC-MS.
8. The sample size for the training set
Not applicable. This is not an AI/ML device; there is no "training set." The studies were designed to validate the physical and chemical performance of the collection device.
9. How the ground truth for the training set was established
Not applicable, as there is no training set for this type of device.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters 'FDA' in a blue square, followed by the words 'U.S. FOOD & DRUG ADMINISTRATION' in blue text.
July 29, 2019
Immunalysis Corporation Wenving (Jessica) Zhu Senior Regulatory Affairs Specialist 829 Towne Center Drive Pomona, CA 91767
Re: K183048
Trade/Device Name: Quantisal II Oral Fluid Collection Device Regulation Number: 21 CFR 862.1675 Regulation Name: Blood specimen collection device Regulatory Class: Class II Product Code: PJD Dated: June 17, 2019 Received: June 18, 2019
Dear Wenying (Jessica) Zhu:
We have reviewed vour Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
{1}------------------------------------------------
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE(@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Kellie B. Kelm, Ph.D. Acting Director Division of Chemistry and Toxicology Devices OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K183048
Device Name
Immunalysis Quantisal™ II Oral Fluid Collection Device
Indications for Use (Describe)
The Quantisal II Oral Fluid Collection Device is intended for the collection, preservation and transport of oral fluid specimens for tetrahydrocannabinol (THC), benzoylecgonine, cocaine, oxycodone, hydrocodone, bacetylmorphine, phencyclidine, amphetamine, buprenorphine, methadone, benzodiazepines and tramadol. This device is for prescription use only.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Image /page/3/Picture/0 description: The image shows the word "IMMUNALYSIS" in white letters on a red background. The word is written in all capital letters and is centered in the image. The red background is a solid color and there are no other objects or details in the image.
510(k) SUMMARY
A. GENERAL INFORMATION
| Applicant Name: | Immunalysis Corporation829 Towne Center DrivePomona, CA 91767Establishment # 2020952 |
|---|---|
| Company Contact: | Wenying (Jessica) ZhuManager, Regulatory AffairsPhone: (909) 451-6697Email: wzhu@immunalysis.com |
| Date Prepared: | July 24, 2019 |
B. DEVICE IDENTIFICATION
| Trade or Proprietary Names: | Immunalysis Quantisal™ II Oral Fluid Collection Device |
|---|---|
| Common Name: | Oral Fluid Collection Device |
C. REGULATORY INFORMATION
| Device Classification Name: | Oral Fluid Drugs Of Abuse And Alcohol Test SpecimenCollection Device |
|---|---|
| Product Codes: | PJD |
| Regulatory Class: | Class II |
| Classification Regulation: | 862.1675 |
| Panel: | Clinical Chemistry (75) |
| Predicate Device: | Saliva Sampler [K942435] |
D. DEVICE DESCRIPTION
The Quantisal II Oral Fluid Collection Device is intended for the collection, preservation and transport of oral fluid.
An oral fluid specimen is collected by placing two cellulose pads affixed to a polypropylene stem (Collector) under the tongue of an individual until a defined volume of saliva has saturated the cellulose pads. The defined volume taken up by the cellulose pads is indicated by coloration (blue) in a window on the stem (volume adequacy). The collector is then separated into two specific pads/stems and transferred into two separate polypropylene tubes (provided) both containing a specific volume of preservative buffer. The tubes are stoppered with provided caps. The specimens are then ready for storage or transport.
The design of two specific pads/stems allows for one aliquot to be used for screening and confirmation testing and the other aliquot to be stored as retain sample for potential second
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the word "IMMUNALYSIS" in white letters on a red background. The word is written in all capital letters and is centered in the image. The background is a solid red color. The letters are bold and have a slight shadow effect.
chance testing.
The Quantisal II Oral Fluid Collection System collects 1 mL of neat oral fluid and dilutes it with 3 mL of preservative buffer. This results in a 1 to 4 dilution factor.
Immunalysis Quantisal II Oral Fluid Collection Device is sold as a stand-alone collection device.
E. INTENDED USE
The Quantisal II Oral Fluid Collection Device is intended for the collection, preservation and transport of oral fluid specimens for tetrahydrocannabinol (THC), benzoylecgonine, cocaine, morphine, codeine, oxycodone, hydrocodone, 6-acetylmorphine, phencyclidine, amphetamine, methamphetamine, buprenorphine, methadone, benzodiazepines and tramadol. This device is for prescription use only.
| Attribute | Predicate DeviceSaliva Sampler [K942435] | Candidate DeviceImmunalysis Quantisal II Oral FluidCollection Device |
|---|---|---|
| Similarities | ||
| Intended Use | Collection and transport of oral fluidspecimens for drug testing | Collection, preservation and transportof oral fluid specimens for drug testing |
| Material | Cellulose pad, polypropylene stem andtransport tube | Same |
| Body Contact | Cellulose pad placed under the tonguefor up to 10 mins | Same |
| Principle | Collecting an oral fluid specimen on acellulose pad and preserving it in abuffer solution contained in acollection tube | Same |
| Sample Collection | Place cellulose pad under the tonguefor collection until blue dye visible inthe window of the stem | Same |
| Transport Tube | Polypropylene tube containingpreservative buffer | Same |
| Sample Matrix | Human oral fluid | Same |
| Differences | ||
| Collector | Collector containing one pad | Collector containing two pads. Thesetwo pads can be separated aftercollection |
| Sample Volume | 1 mL | 1 mL on each pad, 2 mL in total |
| Qty. of TransportTube | 1 transport tube | 2 transport tubes, 1 for each pad |
F. COMPARISON WITH PREDICATE
G. PERFORMANCE CHARACTERISTICS
The following laboratory performance studies were performed to determine substantial
{5}------------------------------------------------
equivalence of the Immunalysis Quantisal II Oral Fluid Collection Devices to the predicate device. Clinical and analytical performances were established using Liquid chromatographytandem mass spectrometry (LC-MS/MS) and Gas chromatography-mass spectrometry (CC-MS).
1. Sample Volume
Fifty oral fluid samples were collected using Quantisal II collectors (collection pad with plastic stem) from fifty volunteers. Prior to collection, each collector (A and B) was weighed. After the volume adequacy indicator turned blue on both A and B collector stems, each collector was weighed again. The difference in weight was noted. Specific gravity of saliva was rounded to 1.000 to compute the volume collection. The results confirmed consistency of sample volume of 1 mL collected by each of Quantisal II collectors, and the volume difference between collector A and B doesn't exceed 15%.
Additional seventy-five oral fluid samples from known drug users were collected using Quantisal II collector. After the volume adequacy indicator turned blue on both A and B collector stems, each collector was weighed and compared to the average weight of collector before collection. The difference in weight was noted. Specific gravity of saliva was rounded to 1.000 to compute the volume collection.
2. Sample Collection Time
Fifty oral fluid samples from volunteers and seventy-five oral fluid samples from known drug users were collected using Quantisal II collection pad with plastic stem). The collection time was documented. The results verified the sample collection time for Quantisal II Oral Fluid Collection Device is within the claimed time of 10 minutes in over 99% of subjects.
3. Drug Recovery
Drug free negative oral fluid spiked with the drug listed in Table 1 at ±25%, +50% of the concentrations also listed in the table were collected and stored in Quantisal II Oral Fluid Collection Device overnight at room temperature. LC-MS/MS or GC-MS testing was performed the next day to determine percentage recovery. The studies demonstrated the Quantisal II Collection Device recovers tested drugs at greater than 80% of the original concentration.
| Drugs | TestingMethod | Concentration(ng/mL) |
|---|---|---|
| THC | GC-MS | 4 |
| Benzoylecgonine | LC-MS/MS | 15 |
| Cocaine | LC-MS/MS | 15 |
| Morphine | LC-MS/MS | 30 |
| Codeine | LC-MS/MS | 30 |
| Oxycodone | LC-MS/MS | 30 |
| Hydrocodone | LC-MS/MS | 30 |
| 6-acetylmorphine | LC-MS/MS | 4 |
| Phencyclidine | LC-MS/MS | 10 |
Table 1. Drug Information
{6}------------------------------------------------
Image /page/6/Picture/0 description: The image contains the word "IMMUNALYSIS" in white letters on a red background. The word is centered and in all capital letters. The background is a solid red color, and the letters are a bright white color.
| Drugs | TestingMethod | Concentration(ng/mL) |
|---|---|---|
| Amphetamine | LC-MS/MS | 50 |
| Methamphetamine | LC-MS/MS | 50 |
| Buprenorphine* | LC-MS/MS | 3 |
| Methadone* | LC-MS/MS | 20 |
| Nordiazepam* | LC-MS/MS | 5 |
| Tramadol* | GC-MS | 50 |
4. Oral Fluid Sample Extraction Efficiency and Stability
Drug free negative oral fluid spiked with drugs listed in Table 1 at +50% of the concentration listed in the table were collected and stored in Quantisal II Oral Fluid Collection Device and tested by LC-MS/MS or GC/MS at each time point at 25°C during the first 24 hours postcollection to determine the point at which extraction was complete and used as a baseline for comparison for determining sample stability. The drug recovery was >80% at 4 hours post collection for all drugs and reached >90% at 24 hours for all drugs to show a complete extraction.
Sample Stability testing was performed using LC-MS/MS or GC/MS at multiple timepoints postcollection at 25℃ and at 2℃ - 8℃. The results are presented in Table 2. The refrigerated study is still ongoing.
| Drugs | Stability at 8-25°C | Stability at 2-8°C |
|---|---|---|
| THC | 10 days | 10 days |
| Benzoylecgonine | 10 days | 10 days |
| Cocaine | 5 days | 10 days |
| Morphine | 10 days | 10 days |
| Codeine | 10 days | 10 days |
| Oxycodone | 10 days | 10 days |
| Hydrocodone | 10 days | 10 days |
| 6-acetylmorphine | 10 days | 10 days |
| Phencyclidine | 10 days | 10 days |
| Amphetamine | 10 days | 10 days |
| Methamphetamine | 10 days | 10 days |
| Buprenorphine | 10 days | 10 days |
| Methadone | 10 days | 10 days |
| Benzodiazepines | 10 days | 10 days |
| Tramadol | 10 days | 10 days |
Table 2. Oral Fluid Sample Stability Results
Additional stability testing was performed on Quantisal II B specimens to verify oral fluid samples containing tested drugs stored in Quantisal II are stable after refrigerated storage. Stability results indicated that the Quantisal II "B" specimen retained for a "split specimen re-
{7}------------------------------------------------
Image /page/7/Picture/0 description: The image shows the word "IMMUNALYSIS" in white letters on a red background. The word is written in all capital letters and is centered in the image. The red background is a solid color and there are no other objects in the image.
confirmation test" were within 100+/- 10% recovery 1 months storage at 2°C - 8°C.
| Drugs | TestingMethod | Concentration(ng/mL) |
|---|---|---|
| THC | GC-MS | 2 |
| Benzoylecgonine | LC-MS/MS | 8 |
| Cocaine | LC-MS/MS | 8 |
| Morphine | LC-MS/MS | 15 |
| Codeine | LC-MS/MS | 15 |
| Oxycodone | LC-MS/MS | 15 |
| Hydrocodone | LC-MS/MS | 15 |
| 6-acetylmorphine | LC-MS/MS | 2 |
| Phencyclidine | LC-MS/MS | 2 |
| Amphetamine | LC-MS/MS | 15 |
| Methamphetamine | LC-MS/MS | 15 |
| Buprenorphine* | LC-MS/MS | 3 |
| Methadone* | LC-MS/MS | 20 |
| Benzodiazepines* | LC-MS/MS | 5 |
| Tramadol* | GC-MS | 50 |
Table 3. Drug Information
5. Sample Transportation Stability
Drug free negative oral fluid spiked with drugs listed in Table 1 at ±50% of the concentration listed in the table were collected and stored in Quantisal II Oral Fluid Collection Device and packed in standard boxes used by common carrier (FedEx). During the 4-day (96 hours) simulated transportation study, the samples were stored in oven/freezer at temperatures ranged from -20℃ to 40℃ to encompass the temperatures likely to occur during shipment of products. The device used as the reference (unstressed) condition was stored continuously at the recommended storage condition at 2℃ - 8℃. LC-MS/MS or GC/MS testing was performed in replicates of two and compared to the reference sample. The studies demonstrated the drug concentration of the sample collected by Quantisal II Oral Fluid Collection Device is within 20% of reference value during transportation.
6. Borosilicate Glass Vial Stability
Drug free expectorated oral fluid was spiked with the drug analyte at a concentration +50% of the concentrations listed in Table 3. The initial concentration of the solution was analyzed by mass spectrometry. Three borosilicate glass vials were introduced sequentially into each aliquot, stored at 25℃ for 48 hours, and then tested using the same analytical method. The drug loss of the samples collected by borosilicate glass vial was within ±10% of the initial value after 48 hours storage at 25°C.
{8}------------------------------------------------
Image /page/8/Picture/0 description: The image contains the word "IMMUNALYSIS" in white letters against a red background. The text is bold and sans-serif. The red background appears to be a rectangle.
7. Clinical Specimens
At least forty deidentified, unaltered drug free clinical oral fluid samples and forty deidentified, unaltered clinical oral fluid samples containing drug for each drug class collected by expectoration (spitting) and Quantisal II Oral Fluid Collection Devices were obtained from clinical research facility, analyzed for drug listed in Table 3 using LC-MS/MS or GC/MS. Quantisal II "A" and "B" results were compared to each other. The expectoration and Quantisal II results were compared against confirmation cutoffs listed in Table 3. A summary of the test results is presented in Table 4. The study demonstrated the accuracy between the two collectors of the Quantisal II Oral Fluid Collection Device when collecting clinical specimens. In no case was the expectorated neat oral fluid positive and the Quantisal II collected samples negative or vice versa. If drugs were present, they were present in samples from both oral fluid expectoration and device collection methods.
{9}------------------------------------------------
Image /page/9/Picture/0 description: The image shows the word "IMMUNALYSIS" in white letters on a red, hexagon-shaped background. The word is written in all capital letters and is centered on the background. The red background is a bright, saturated color. The font is sans-serif and bold.
Table 4. Summary of Clinical Specimens Test Results
| Drug Class | Drug | Sample Type | Number of Samplesfor Each Drug | Quantisal II A and Bsamples within ±15% ofeach other | Quantisal II A/BAgreement withExpectorated Samples |
|---|---|---|---|---|---|
| THC(40 drug-free40 containing drug) | 9-THC | Drug-Free | 40 | 100% (40/40) | 100% (40/40) |
| 9-THC | Containing drug | 40 | 100% (40/40) | 100% (40/40) | |
| Cocaine and CocaineMetabolites(80 drug-free80 containing drug) | Benzoylecgonine | Drug-Free | 40 | 100% (40/40) | 100% (40/40) |
| Containing drug | 40 | 100% (40/40) | 100% (40/40) | ||
| Cocaine | Drug-Free | 40 | 100% (40/40) | 100% (40/40) | |
| Containing drug | 40 | 100% (40/40) | 100% (40/40) | ||
| Morphine | Drug-Free | 40 | 100% (40/40) | 100% (40/40) | |
| Containing drug | 40 | 100% (40/40) | 100% (40/40) | ||
| Codeine | Drug-Free | 40 | 100% (40/40) | 100% (40/40) | |
| Containing drug | 40 | 100% (40/40) | 100% (40/40) | ||
| Opiates(200 drug-free178 containing drug) | Oxycodone | Drug-Free | 40 | 100% (40/40) | 100% (40/40) |
| Containing drug | 40 | 100% (40/40) | 100% (40/40) | ||
| Hydrocodone | Drug-Free | 40 | 100% (40/40) | 100% (40/40) | |
| Containing drug | 18 | 100% (18/18) | 100% (18/18) | ||
| 6-AM | Drug-Free | 40 | 100% (40/40) | 100% (40/40) | |
| Containing drug | 40 | 100% (40/40) | 100% (40/40) | ||
| PCP(40 drug-free40 containing drug) | PCP | Drug-Free | 40 | 100% (40/40) | 100% (40/40) |
| Containing drug | 40 | 100% (40/40) | 100% (40/40) | ||
| Amphetamine(40 drug-free40 containing drug) | Amphetamine | Drug-Free | 40 | 100% (40/40) | 100% (40/40) |
| Containing drug | 40 | 100% (40/40) | 100% (40/40) | ||
| Methamphetamine(40 drug-free40 containing drug) | Methamphetamine | Drug-Free | 40 | 100% (40/40) | 100% (40/40) |
| Containing drug | 40 | 100% (40/40) | 100% (40/40) | ||
| Drug Class | Drug | Sample Type | Number of Samplesfor Each Drug | Quantisal II A and Bsamples within ±15% ofeach other | Quantisal II A/BAgreement withExpectorated Samples |
| Buprenorphine(40 drug-free40 containing drug) | Buprenorphine | Drug-Free | 40 | 100% (40/40) | 100% (40/40) |
| Buprenorphine | Containing drug | 40 | 100% (40/40) | 100% (40/40) | |
| Methadone(40 drug-free40 containing drug) | Methadone | Drug-Free | 40 | 100% (40/40) | 100% (40/40) |
| Methadone | Containing drug | 40 | 100% (40/40) | 100% (40/40) | |
| Benzodiazepines(40 drug-free40 containing drug) | Nordiazepam | Drug-Free | 40 | 100% (40/40) | 100% (40/40) |
| Nordiazepam | Containing drug | 40 | 100% (40/40) | 100% (40/40) | |
| Tramadol(40 drug-free40 containing drug) | Tramadol | Drug-Free | 40 | 100% (40/40) | 100% (40/40) |
| Tramadol | Containing drug | 40 | 100% (40/40) | 100% (40/40) |
{10}------------------------------------------------
Image /page/10/Picture/0 description: The image shows the word "IMMUNALYSIS" in white letters. The letters are bolded and have a slight shadow effect. The word is set against a red, hexagon-shaped background.
{11}------------------------------------------------
8. Expectorated Oral Fluid Samples Processed Through Quantisal II (Dipping Study)
At least sixty deidentified, unaltered drug containing oral fluid samples were collected by expectoration (spitting) at clinical research facility, and analyzed using LC-MS/MS or GC/MS. A minimum of ten samples of each drug were within ±50% of the confirmation cutoffs listed in Table 3. A Quantisal II device was introduced into each expectorated sample. The next day, Quantisal II samples A and B were analyzed by mass spectrometry. 899/900 paired results meet the criteria that Quantisal II A and B concentrations were within 15% of each other. 899/900 paired results meet the criteria that Quantisal II concentration was within ±20% of the expectoration result. This study demonstrated no difference in drug concentrations in oral fluid when expectorated samples are compared to the same oral fluid subjected to Quantisal II collection regardless of drug class. The Quantisal II oral fluid collection device does not introduce bias to quantitative and qualitative results of expectoration neat oral fluid sample (clinical truth).
{12}------------------------------------------------
Image /page/12/Picture/0 description: The image shows the word "IMMUNALYSIS" in white letters on a red background. The word is written in all capital letters and is bolded. The background is a solid red color. The image is simple and straightforward, with the focus being on the word itself.
H. CONCLUSION
The information provided in this pre-market notification demonstrates that the Immunalysis Quantisal II Oral Fluid Collection Device is substantially equivalent to the legally marketed predicate device for its intended use.
§ 862.1675 Blood specimen collection device.
(a)
Identification. A blood specimen collection device is a device intended for medical purposes to collect and to handle blood specimens and to separate serum from nonserum (cellular) components prior to further testing. This generic type device may include blood collection tubes, vials, systems, serum separators, blood collection trays, or vacuum sample tubes.(b)
Classification. Class II.